This Review from Neurodegenerative Disease Management explores light therapy for Alzheimer’s disease and related dementias, and how to maximize treatment impact.
Browsing: Cognitive/neurodegenerative disorders
The use of on-a-chip technologies has seen enormous growth across the biomedical sciences in recent years, but how can this approach be harnessed to further understand dementia and develop new therapies?
Research suggests that family history explains conflicting study results for Alzheimer’s disease risk gene TOMM40.
Jutley et al. discuss established glaucoma treatments, review promising new neuroprotective agents, and explore potential future treatments targeting the neurodenegerative processes in glaucoma.
Michael discusses his work, progress towards diagnosis of chronic traumatic encephalopathy in life and his thoughts on the latest in CTE research.
Research suggests increasing synaptic activity could alleviate SMA symptoms: motor function of mice was improved when treated with a glutamate receptor stimulant.
Both lithium and rapamycin could prevent the secondary nerve cell damage caused by the overproduction of glutamate after a traumatic brain injury.
Restoration of CB1 signaling in aging individuals could become an effective treatment for age-related cognitive impairments.
Amyloid positron emission tomography (aPET) measurement of Alzheimer’s disease (AD) pathology could improve the accurate diagnosis of cognitive disorders.
The Biogerontology Research Foundation looks to deep-learning and artificial intelligence to accelerate drug discovery for aging and age-associated diseases, including neurodegenerative disease.